CClinicalTrials.gg
CompletedNCT00653692Updated Feb 21, 2013

Fetal Neurobehavior in Poly-drug Dependent Women

An observational study in Poly Drug Exposed Pregnancies, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to female participants aged 18 Years to 41 Years. Per ClinicalTrials.gov, last updated 2013-02-21.

Sponsored by Johns Hopkins University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
29
Ages
18 Years to 41 Years
Sex
Female
01

Study summary

This project examines fetal neurobehavior and maternal physiology in poly-drug dependent women. This study also evaluates infant neonatal abstinence syndrome, infant neurobehavior and vagal tone in the post-partum period.

Read the detailed description

Little is known about the link between maternal physiology, fetal neurobehavior and neonatal abstinence syndrome in multiply drug-dependent women. Previous research by this group of investigators has found that the severity of neonatal abstinence syndrome in methadone exposed infants is related to maternal vagal tone changes in response to methadone during pregnancy. While previous research has focused on drug abstinent, methadone maintained women, most drug dependent pregnant women are poly-substance abusers who also use prescription psychiatric medications, alcohol and nicotine. This protocol seeks to further our understanding of the effects of multiple drugs on the fetus, including the co-variate effects of maternal psychological status. Infant neurobehavior and vagal tone will also be evaluated. This research will extend our knowledge of fetal neurobehavioral development and neonatal abstinence syndrome in a realistic population of poly-drug dependent women, potentially altering the way in which these women are evaluated and their infants monitored and treated for neonatal abstinence syndrome.

02

Conditions studied

  • Poly Drug Exposed Pregnancies

Keywords

  • Substance abuse
  • fetal development
  • vagal tone
03

In context

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 41 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Poly drug dependent pregnant women

Inclusion criteria

  • Age 18-41
  • Single intrauterine fetus
  • Free of significant maternal or fetal significant health complications

Exclusion criteria

Exclusion Criteria:

  • Development of significant maternal or fetal health complications
  • Significant maternal psychopathology that would preclude informed consent
  • Unwilling or unable to receive methadone at prescribed times
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
29 participants (actual)

Groups and cohorts

  • Observational

    Poly drug dependent women

06

What researchers measure

Primary outcomes

  1. fetal heart rate

    Time frame: 120 minutes

  2. fetal movement

    Time frame: 120 minutes

Secondary outcomes

  1. neonatal abstinence syndrome

    Time frame: 4 days

07

Study locations

1 site
  • The Center for Addiction and Pregnancy
    Baltimore, Maryland 21224, United States
08

References and documents

Publications

  • Jansson LM, Di Pietro JA, Elko A, Williams EL, Milio L, Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend. 2012 May 1;122(3):213-9. doi: 10.1016/j.drugalcdep.2011.10.003. Epub 2011 Oct 29. PubMed 22041255 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00653692
Lead sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Lauren M. Jansson (Associate Professor of Pediatrics Johns Hopkins University School of Medicine, National Institute on Drug Abuse (NIDA)) — Principal investigator
First posted
Apr 7, 2008
Start date
May 2007
Primary completion
Feb 2010
Completion
Aug 2010
Last update
Feb 21, 2013

Study contacts

Lauren M Jansson, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion